1. Home
  2. IMUX vs BDSX Comparison

IMUX vs BDSX Comparison

Compare IMUX & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • BDSX
  • Stock Information
  • Founded
  • IMUX 2016
  • BDSX 2005
  • Country
  • IMUX United States
  • BDSX United States
  • Employees
  • IMUX N/A
  • BDSX N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • BDSX Precision Instruments
  • Sector
  • IMUX Health Care
  • BDSX Health Care
  • Exchange
  • IMUX Nasdaq
  • BDSX Nasdaq
  • Market Cap
  • IMUX 107.3M
  • BDSX 115.4M
  • IPO Year
  • IMUX N/A
  • BDSX 2020
  • Fundamental
  • Price
  • IMUX $0.69
  • BDSX $0.31
  • Analyst Decision
  • IMUX Strong Buy
  • BDSX Strong Buy
  • Analyst Count
  • IMUX 6
  • BDSX 5
  • Target Price
  • IMUX $11.60
  • BDSX $1.75
  • AVG Volume (30 Days)
  • IMUX 1.4M
  • BDSX 25.3M
  • Earning Date
  • IMUX 05-15-2025
  • BDSX 05-13-2025
  • Dividend Yield
  • IMUX N/A
  • BDSX N/A
  • EPS Growth
  • IMUX N/A
  • BDSX N/A
  • EPS
  • IMUX N/A
  • BDSX N/A
  • Revenue
  • IMUX N/A
  • BDSX $74,463,000.00
  • Revenue This Year
  • IMUX N/A
  • BDSX $19.92
  • Revenue Next Year
  • IMUX N/A
  • BDSX $29.03
  • P/E Ratio
  • IMUX N/A
  • BDSX N/A
  • Revenue Growth
  • IMUX N/A
  • BDSX 35.76
  • 52 Week Low
  • IMUX $0.56
  • BDSX $0.17
  • 52 Week High
  • IMUX $2.11
  • BDSX $2.04
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 27.13
  • BDSX 38.82
  • Support Level
  • IMUX $0.56
  • BDSX $0.29
  • Resistance Level
  • IMUX $0.95
  • BDSX $0.37
  • Average True Range (ATR)
  • IMUX 0.07
  • BDSX 0.06
  • MACD
  • IMUX -0.03
  • BDSX 0.01
  • Stochastic Oscillator
  • IMUX 22.66
  • BDSX 38.80

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: